
PRP, low-level laser therapy and FDA-approved topical and oral treatments. Hereditary hair loss affects an estimated 80 million Americans, and many markets have no dedicated clinic to serve them.
Book a Strategy CallThe gap between demand and clinical supply is one of the widest in cash-pay health: salons cannot offer clinical PRP, and many markets have no dedicated clinic.
Patients are already searching. The question is who opens the clinic first, and our independent clinic launch program is built for that.
Hair regeneration works as a standalone model and as a powerful complement to any longevity, hormone or aesthetics clinic already serving an aging demographic.
Platelet-rich plasma from the patient's own blood, prepared and injected in a single visit. One of the most clinically documented regenerative hair treatments, and the anchor service.
FDA-cleared devices, standalone or as an adjunct, with in-clinic sessions and at-home device sales.
Minoxidil and finasteride remain the only FDA-approved medications for androgenetic alopecia (October 2026). Prescriber-directed, inexpensive to stock, and the most defensible foundation for a hair clinic menu.
Scalp microneedling combined with topical protocols. Lower barrier to entry and add-on revenue per visit.
GHK-Cu (copper peptide) applied topically, within the limits of that route; injectable GHK-Cu sits in a different regulatory position. See the peptide therapy status table.
Hereditary hair loss is driven by DHT, so hair and hormone care share patients and prescribers, which makes hormone optimization the most natural second category to add.
PRP is a medical procedure: it needs physician oversight, and your scope of services sets the oversight model in your state.
This category has a clean path and a messy one. The clean path is autologous PRP, FDA-cleared lasers, and FDA-approved topical and oral therapy. The messy path is cellular products and exosomes, where the FDA has approved nothing for hair loss and enforcement is active. ACG builds on the first.
Our team has already done the regulatory navigation. The supplier relationships, Medical Director introductions, and compliance framework are built into the engagement, not billed separately.
All regenerative hair treatments require physician oversight. ACG introduces vetted Medical Directors with category experience in all 50 states.
ACG builds your treatment menu on well-established modalities and steers you away from products carrying active FDA enforcement risk, exosomes above all.
Who can perform scalp injections, what oversight is required, and how your entity structure affects liability, mapped for your state.
Consent forms, treatment protocols and patient intake, built for a hair clinic.
Hair regeneration carries fewer paid advertising restrictions than peptide or hormone categories, except PRP: Google's cell therapy ad policy bars ads that promote it. Before-and-after imagery still has rules, and ACG supplies the compliant framing.
Hair loss is not a one-visit problem. A common PRP program is one session a month for three months, then a booster every six months (ISHRS).
3 + Boosters
Three monthly sessions, then a booster every six months, which brings patients back.
Independent MD
No medical background is required to own the business. An independent, state-licensed Medical Director directs all clinical care.
Men and Women
Hereditary hair loss affects men and women alike, so the patient base is broad.
Launch Window
From keys received, market and regulatory conditions permitting.
Straight answers on PRP, exosomes, equipment and pricing. Anything else, ask on the strategy call.
View All FAQsCellular and tissue-based products often share a treatment room with PRP, but carry a regulatory burden autologous PRP largely does not. Know how your product is classified under 21 CFR Part 1271, and what your claims do to that classification.
A supplier calling a product 361 compliant is making a marketing claim, not a regulatory determination. Knowing the difference is the whole ballgame in this category.

Your market is searching, and nobody is answering. Talk with Grayson Miller about local demand, a menu that holds up and what opening takes. No pitch. No obligation.
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Knowing the rules is the foundation of every clinic we help launch.
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.